Asthma and COPD: what does the future hold?

> Dear Executive,
>
> A strategic analysis from Espicom Business Intelligence...

Asthma and COPD Drug Discoveries: what the future holds

> The global asthma and COPD market is currently worth around US$20 billion.
> The top twelve pharmaceutical products by value had combined global sales
> of US$15.7 billion in 2005. Six brands had sales in excess of US$1
> billion. Combined sales of the top ten products were 21.1% higher than in
> 2004.
>
> A number of older therapies, for asthma in particular, are widely
> available
> generically and there is fierce competition in the market. The asthma
> market accounts for the majority of the total and is valued at around
> US$15
> billion. The COPD market is currently valued at US$4 - US$5 billion and is
> set to double in the next five years.
>
> Future market growth will be driven by increasing disease awareness, an
> increasing patient pool, both in the paediatric asthma sector and the
> ageing population susceptible to COPD, and the launch of newer, more
> expensive therapies targeting areas of high unmet clinical need. These
> will be offset to some extent by the launch of new generics and the sales
> erosion of monotherapies by combination products.
>
> A rapidly expanding sector...
>
> An estimated 300 million people around the world have asthma and the
> European Federation of Allergy and Airway Diseases Patients Association
> have indicated that this could increase to 400-450 million by 2025.
> Around
> 30 million people in Europe have asthma, 6 million of whom have severe
> symptoms and around 1.5 million live in fear of dying from an attack.
>
> COPD is one of the top five causes of disability and death in industrial
> societies. According to the WHO, COPD is the fourth leading cause of
> death
> worldwide, based on 2004 data. In the US, COPD is projected to be the
> third leading cause of death by 2020.
>
> Results of the National Health Interview Survey in the US indicate that
> 12.1 million adults over the age of 25 reported being diagnosed with COPD
> in 2001. Of these, 9.2 million reported being diagnosed with chronic
bronchitis, 2 million with emphysema and 0.9 million with both conditions.

According to the National Heart, Blood and Lung Institute, this compares with around 24 million adults in the US who have evidence of impaired lung function, which suggests COPD is under-diagnosed.

According to the European Respiratory Society, the total cost of asthma in Europe is €17.7 billion per year (White Book, 2003). In the UK, around 5.2 million people are currently receiving treatment for asthma. Of these, 1.1 million are children, equivalent to one in ten. According to Asthma UK, asthma costs the NHS an average of £889 million per year.

Asthma and COPD Drug Discoveries: what the future holds provides a complete insight into the prospects for companies and products that are driving this high growth US$20 billion sector.

THIS REPORT ANSWERS CRITICAL QUESTIONS...

Which products will win out in the race to maximise revenues?
What therapeutic approach will dominate?
Which companies are involved?
What will the market landscape look like in 2011?

AND PROVIDES...

Product/market forecast by value 2006/2011 for current and future therapies
15 key products assessed
Market context
Competitive evaluation
Research reviews

NEW AND ESTABLISHED THERAPY APPROACHES COVERED

Beta-2 Agonists
Inhaled Corticosteroids
Combination Therapies
Leukotrine Receptor Antagonists
Anti-Immunoglobulin E Therapy
Muscarinic Antagonists
PDE-IV Inhibitors
> Asthma & COPD Drug Discoveries: what the future holds is available now in
> pdf via email and printed formats for just £1295/US$2655/€2330.
>
> > TO ORDER YOUR COPY TODAY GO TO:
> >
> >
> >
> > We hope you enjoy receiving this information from Espicom Business
> > Intelligence and you are welcome to forward this email to your friends and
> > colleagues. Anyone who wishes to benefit from this service should go to
> > our registration page:
> >
> > If, however, you do not wish to receive future issues, please reply to
> > this
> > message, typing 'no thanks' in the subject box of your email.
>
> Regards,
>
> Ian Taylor,
> Editorial Director
>
>
> Espicom Limited
> Registered Office: Lincoln House, City Fields Business Park, City Fields
> Way, Chichester, West Sussex, PO20 2FS, UK.
> Tel +44 (0)1243 533322 Fax +44 (0)1243 533418 Sales_Desk@espicom.com
> Company Registration No. 2768600
>
> Espicom USA Inc., 116 Village Boulevard, Princeton Forrestal Village,
> Princeton, NJ 08540-5799, USA.
> Tel: +1 (609) 951 2227 Fax +1 (609) 734 7428 USA_SalesDesk@espicom.com
> Registered Office: 600 College Road East, Princeton, New Jersey 08540,
> USA.
> Taxpayer Identification No. 22-3561984
>
>